What was the market valuation of the US hereditary angioedema-therapeutics market in 2024?

The market valuation was $1761.4 Million in 2024. Read More

What is the projected market valuation for the US hereditary angioedema-therapeutics market by 2035?

The projected valuation for 2035 is $2739.7 Million. Read More

What is the expected CAGR for the US hereditary angioedema-therapeutics market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.1%. Read More

Which drug class had the highest valuation in the US hereditary angioedema-therapeutics market in 2024?

The C1 Esterase Inhibitor drug class had a valuation of $600.0 Million in 2024. Read More

What are the projected valuations for Type I and Type II hereditary angioedema by 2035?

Type I is projected to reach $1600.0 Million, while Type II is expected to reach $1139.7 Million by 2035. Read More

Which route of administration is anticipated to have the highest valuation in the US hereditary angioedema-therapeutics market by 2035?

The subcutaneous route is anticipated to reach $1100.0 Million by 2035. Read More

What distribution channel had the highest valuation in 2024 for the US hereditary angioedema-therapeutics market?

The hospital pharmacy distribution channel had a valuation of $704.56 Million in 2024. Read More

Which key player is associated with the development of therapies for hereditary angioedema?

Takeda Pharmaceutical Company Limited is one of the key players in the development of therapies for hereditary angioedema. Read More

What was the valuation of the on-demand treatment segment in the US hereditary angioedema-therapeutics market in 2024?

The on-demand treatment segment was valued at $761.4 Million in 2024. Read More

What is the projected growth for the Kallikrein Inhibitor drug class by 2035?

The Kallikrein Inhibitor drug class is projected to reach $600.0 Million by 2035. Read More

US Hereditary Angioedema Therapeutics Market

ID: MRFR/HC/15214-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Hereditary Angioedema Therapeutics Market Research Report: Size, Share, Trend Analysis By Types (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

US Hereditary Angioedema Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Type I
  2. 4.1.2 Type II
2. 4.2 Food, Beverages & Nutrition, BY Drug Class (USD Million)
  1. 4.2.1 C1 Esterase Inhibitor
  2. 4.2.2 Selective Bradykinin B2 Receptor Antagonist
  3. 4.2.3 Kallikrein Inhibitor
  4. 4.2.4 Others
3. 4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.3.1 Prophylaxis
  2. 4.3.2 On-demand
4. 4.4 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
  1. 4.4.1 Intravenous
  2. 4.4.2 Subcutaneous
  3. 4.4.3 Oral
5. 4.5 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  1. 4.5.1 Hospital Pharmacy
  2. 4.5.2 Retail Pharmacy
  3. 4.5.3 Online Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 CSL Behring (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Shire (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pharming Group N.V. (NL)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 BioCryst Pharmaceuticals, Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sobi (SE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ferring Pharmaceuticals (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Grifols S.A. (ES)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
10. 6.10 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
12. 6.12 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 (% SHARE)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
20. 6.20 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
21. 6.21 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

Type I
Type II

Food, Beverages & Nutrition By Drug Class (USD Million, 2025-2035)

C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Others

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

Prophylaxis
On-demand

Food, Beverages & Nutrition By Route of Administration (USD Million, 2025-2035)

Intravenous
Subcutaneous
Oral

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”